Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 3 2

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 4Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Melanoma 4Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × lifileucel × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06151847 2026-04-30

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

University of Kansas Medical Center

Phase 2 Completed
11 enrolled
Dermatologic

Melanoma

NCT07288203 2026-04-20

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Iovance Biotherapeutics, Inc.

Phase 2 Active not recruiting
100 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT02360579 2026-03-25

LN-144

Iovance Biotherapeutics, Inc.

Phase 2 Completed
220 enrolled 16 charts
Dermatologic

Melanoma

NCT06481592 2025-10-30

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
60 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡